3-Trifluoromethyl-4-nitro-5-arylpyrazoles are novel KATP channel agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 3, 2004, Pages 813-816

  Peat, Andrew J ^a   Townsend, Claire ^a   McKay, M Craig ^a   Garrido, Dulce ^a   Terry, Christopher M ^a   Wilson, Jayme L R ^a   Thomson, Stephen A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIAZOXIDE; FUNCTIONAL GROUP; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; NITRO DERIVATIVE; POTASSIUM CHANNEL STIMULATING AGENT; PYRAZOLE DERIVATIVE; RECEPTOR SUBTYPE; SULFONYLUREA RECEPTOR;

AGONIST; ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

EID: 1642575087     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.10.066     Document Type: Article

References (34)

1. Cook D.L., Hales C.N. Nature. 311:1984;271.
2. Standen N.B., Quayle J.M., Davies N.W., Brayden J.E., Huang Y., Nelson M.T. Science. 245:1989;177.
3. Noma A. Nature. 305:1983;147.
4. Quast U. Naunyn-Schmiedebergs Arch. Pharmacol. 354:1996;213.
5. Bernadi H., Fosset M., Lazdunski M. Proc. Natl. Acad. Sci. U.S.A. 85:1988;9816.
6. Aguilar-Bryan L., Bryan J., Nakazaki M. Recent Prog. Horm. Res. 56:2001;47.
7. Wollheim C.B., Sharp G.W.G. Physiol. Rev. 61:1981;914.
8. For recent reviews, see: Bryan J., Aguilar-Bryan L. Biochim. Biophys. Acta. 1461:1999;285.
9. Seino S., Miki T., Yano H. Endocrine Updates. 11:2001;91.
10. Ashcroft S.J.H. J. Membr. Biol. 176:2000;187.
11. Gribble F.M., Ashcroft F.M. Metab., Clin. Exp. 49:2000;3.
12. Newgreen D.T., Bray K.M., McHarg A.D., Weston A.H., Duty S., Brown B.S., Kay P.B., Edwards G., Longmore J., Southerton J.S. Br. J. Pharmacol. 100:1990;605.
13. Escande D., Thuringer D., Leguern S., Cavero I. Biochem. Biophys. Res. Commun. 154:1988;620.
14. Yokoshiki H., Sunagawa M., Seki T., Sperelakis N. Am. J. Physiol. 274:1998;C25.
15. Garrino M.G., Plant T.D., Henquin J.C. Br. J. Pharmacol. 98:1989;957.
16. Greenwood R.H., Mahler R.F., Hales C.N. Lancet. 28:1976;444.
17. Bjork E., Berne C., Kampe O., Wibell L., Oskarsson P., Karlsson F.A. Diabetes. 45:1996;1427.
18. Alemzadeh R., Langley G., Upchurch L., Smith P., Slonim A.E. J. Clin. Endocrinol. Metab. 83:1998;1911.
19. Honey M., Cotter L., Davies N., Denison D. THORAX. 35:1980;269.
20. Falk J.L., Tang M. Physiol. Behavior. 9:1972;259.
21. Uno H., Kemnitz J.W., Cappas A., Adachi K., Sakuma A., Kamoda H. J. Dermatol. Sci. 1:1990;183.
22. Buhl A.E., Waldon D.J., Conrad S.J., Mulholland MlJ., Shull K.L., Kubicek M.F., Johnson G.A., Brunden M.N., Stefanski K.J., Stehle R.G. J. Invest. Dermatol. 98:1992;315.
23. Lebrun P., Arkhammar P., Antoine Q.A., Hansen J.B., Pirotte B. Diabetologia. 43:2000;723.
24. De Tullio P., Pirotte B., Lebrun P., Fontaine J., Dupont L., Antoine M.-H., Ouedraogo R., Khelili S., Maggetto C., Masereel B., Diouf O., Podona T., Delarge J. J. Med. Chem. 39:1996;937.
25. Peat A.J., Townsend C., Worley J.F. III, Allen S.H., Garrido D., Mertz R.J., Pfohl J.L., Terry C.M., Truax J.F., Veasey R.L., Thomson S.A. Bioorg. Med. Chem. Lett. 12:2002;2977.
26. Nielsen F.E., Bodvarsdottir T.B., Worsaae A., MacKay P., Stidsen C.E., Boonen H.C.M., Pridal L., Arkhammar P.O.G., Wahl P., Ynddal L., Junager F., Dragsted N., Tagmose T.M., Mogensen J.P., Koch A., Treppendahl S.P., Hansen J.B. J. Med. Chem. 45:2002;4171.
27. Pfohl J.L., Worley J.F. III, Condreay J.P., An G., Apolito C.J., Kost T.A., Truax J.F. Receptors Channels. 8:2002;99.
28. Janssen J.W.A.M., Koeners H.J., Habraken C.L. J. Org. Chem. 38:1973;1777.
29. Almirante N., Cerri A., Fedrizzi G., Marazzi G., Santagostino M. Tetrahedron Lett. 39:1998;3287.
30. Compound 6 was isolated as a mixture of keto and hydrate forms.
31. Nickson T.E. J. Org. Chem. 53:1988;3870.
32. Compound 7 contains ca. 5% of the difluoro analogue. Use of 0.1% aqueous HCl gave ca. 35% of the difluoro analogue.
33. 1H NMR and LC/MS) consistent with the reported structures and compound purity was determined to be >95%. Compounds 2 and 5 are available commercially.
34. Gribble F.M., Ashfield R., Ammala C., Ashcroft F.M. J. Physiol. 487:1997;87.